Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: a Systematic Review.
Fiche publication
Date publication
septembre 2019
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Estevinho MM, Rocha C, Correia L, Lago P, Ministro P, Portela F, Trindade E, Afonso J, Peyrin-Biroulet L, Magro F,
Lien Pubmed
Résumé
We performed a systematic review of changes in fecal and colon microbiomes of patients with inflammatory bowel diseases (IBD) receiving treatment with monoclonal antibodies against tumor necrosis factor (TNF), integrins, or cytokines. We explored associations among microbiome composition and functions (at baseline and throughout the treatment) and therapy-related outcomes to determine whether colon or fecal microbiomes might be used as biomarkers of response to therapy.
Mots clés
adalimumab, certolizumab, infliximab, vedolizumab
Référence
Clin. Gastroenterol. Hepatol.. 2019 Sep 14;: